In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
As of close of business last night, AbCellera Biologics Inc’s stock clocked out at $3.12, down -1.27% from its previous closing price of $3.16. In other words, the price has decreased by -$1.27 from its previous closing price. On the day, 7.37 million shares were traded.
Ratios:
To gain a deeper understanding of ABCL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.15 and its Current Ratio is at 10.15. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On February 22, 2024, The Benchmark Company Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $9.
On December 05, 2023, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $6.KeyBanc Capital Markets initiated its Overweight rating on December 05, 2023, with a $6 target price.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 40.28 while its Price-to-Book (P/B) ratio in mrq is 0.91.
Stock Price History:
Over the past 52 weeks, ABCL has reached a high of $3.68, while it has fallen to a 52-week low of $1.89. The 50-Day Moving Average of the stock is 32.91%, while the 200-Day Moving Average is calculated to be 17.10%.
Shares Statistics:
A total of 298.36M shares are outstanding, with a floating share count of 223.95M. Insiders hold about 24.97% of the company’s shares, while institutions hold 41.09% stake in the company.
Earnings Estimates
The dynamic stock of AbCellera Biologics Inc (ABCL) is currently being evaluated by a team of 6.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.14 and low estimates of -$0.19.
Analysts are recommending an EPS of between -$0.58 and -$0.76 for the fiscal current year, implying an average EPS of -$0.64. EPS for the following year is -$0.63, with 5.0 analysts recommending between -$0.37 and -$0.81.
Revenue Estimates
In the current quarter, 9 analysts expect revenue to total $7.55M. It ranges from a high estimate of $21.06M to a low estimate of $4.67M. As of the current estimate, AbCellera Biologics Inc’s year-ago sales were $7.32MFor the next quarter, 9 analysts are estimating revenue of $7.57M. There is a high estimate of $20.66M for the next quarter, whereas the lowest estimate is $4.31M.
A total of 10 analysts have provided revenue estimates for ABCL’s current fiscal year. The highest revenue estimate was $68.74M, while the lowest revenue estimate was $16.03M, resulting in an average revenue estimate of $26.06M. In the same quarter a year ago, actual revenue was $28.83MBased on 8 analysts’ estimates, the company’s revenue will be $52.58M in the next fiscal year. The high estimate is $175.91M and the low estimate is $22.9M.
